Last updated: February 3, 2026
Executive Summary
Ultravist 300 (Iopromide) in plastic containers is a globally used contrast agent in diagnostic imaging, particularly computed tomography (CT). The drug's market landscape is influenced by rising demand for advanced imaging modalities, shifts towards safer and more environmentally friendly packaging, and evolving regulatory frameworks. This report provides a comprehensive analysis of the current market dynamics, financial trends, competitive landscape, regulatory considerations, and future growth trajectories for Ultravis 300 in plastic containers.
Key insights:
-
The global contrast agent market is projected to reach USD 4.2 billion by 2028, with a compound annual growth rate (CAGR) of approximately 6.2% (2023–2028) [1].
-
Ultravis 300, as a high-osmolar contrast agent, faces increased competition from low-osmolar and iso-osmolar alternatives.
-
The transition to plastic containers aligns with environmental sustainability trends, influencing manufacturing costs and consumer acceptance.
-
Market growth is driven by expanding radiology departments, technological advancements, and increased healthcare expenditure, especially in emerging markets.
Market Overview for Ultravis 300
| Parameter |
Details |
| Active Ingredient |
Iopromide (Ultravist 300) |
| Packaging Format |
Plastic containers (single-dose and multidose vials) |
| Approved Indications |
Diagnostic CT imaging |
| Key Markets |
North America, Europe, Asia-Pacific, Latin America |
| Major Manufacturers |
Bayer AG, Guerbet, Lantheus, Bracco |
Note: The focus on plastic containers addresses regulatory pressures, environmental sustainability, and patient safety concerns enhancing market penetration.
Market Drivers
Increasing Demand for Diagnostic Imaging
The global demand for advanced imaging techniques, notably CT scans, propels contrast agent use. The proliferation of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders fuels the need for detailed imaging.
Rise in Healthcare Expenditure
Emerging markets like China and India witness healthcare investments expanding access to radiology services, boosting contrast agent consumption.
Regulatory and Environmental Shifts
Regulatory agencies are advocating for environmentally friendly packaging solutions. Plastic containers reduce risks of spillage and contamination, satisfying safety and environmental standards.
Technological Innovation
The development of safer, lower-osmolar contrast media reduces adverse reactions, expanding patient eligibility and usage frequency.
COVID-19 Pandemic Impact
While initial disruptions occurred, ongoing imaging needs and adaptations in healthcare delivery sustain long-term growth potential.
Market Restraints and Challenges
| Restraint |
Impact |
| Regulatory Constraints |
Stringent approval processes globally may delay market entry or reformulation workflows. |
| Competition from Low/ISO-osmolar Agents |
These alternatives may displace high-osmolar antigens like Ultravis 300 in some markets. |
| Environmental Concerns |
Plastic packaging, despite advantages, faces scrutiny over sustainability. |
| Supply Chain Disruptions |
Disruptions in raw material sourcing or manufacturing capacity can impair supply. |
Competitive Landscape
| Company |
Product Portfolio |
Market Share (Estimate) |
Notable Strategies |
| Bayer AG |
Ultravist 300, MultiHance |
45% |
Expanding manufacturing capacity, sustainability initiatives |
| Guerbet |
Lipiodol, Xenetix |
20% |
Focus on innovation, eco-friendly packaging |
| Lantheus |
Definity, Gastrovist |
15% |
Diversification, regional expansion |
| Bracco |
Isovue, Endorem |
10% |
Regulatory engagement, packaging improvements |
Market share figures approximate and derived from industry reports [2].
Financial Trajectory and Revenue Projections
Historical Revenue Trends (2018–2022)
| Year |
Global Ultravis 300 Revenue (USD millions) |
CAGR (2018–2022) |
Comments |
| 2018 |
450 |
- |
Entry-level, high-osmolar contrast media |
| 2019 |
470 |
1.4% |
Steady growth |
| 2020 |
490 |
1.1% |
Pandemic effects, short-term dips |
| 2021 |
520 |
6.1% |
Recovery, increased imaging demand |
| 2022 |
550 |
5.8% |
Market expansion |
Forecasted Revenue (2023–2028)
| Year |
Estimated Revenue (USD millions) |
Assumed CAGR |
Key Drivers |
| 2023 |
585 |
6.2% |
Continued adoption, new market entries |
| 2024 |
620 |
6.0% |
Technological advances, packaging shifts |
| 2025 |
660 |
6.0% |
Aging population, technology innovations |
| 2026 |
700 |
6.0% |
Regulatory approvals, global expansion |
| 2027 |
745 |
6.0% |
Market consolidation, eco packaging focus |
| 2028 |
792 |
6.0% |
Increased healthcare spending |
Impact of Packaging Shift to Plastic
Transition to plastic containers is projected to:
-
Reduce costs by approximately 10–15% in manufacturing due to simplified sterilization and handling processes [3].
-
Enhance global distribution efficiency given lighter weight and improved durability.
-
Enable smaller, pre-filled, single-dose formats, increasing convenience and compliance.
Regulatory Trends and Market Entry Considerations
| Regulatory Agency |
Focus Areas |
Implications |
| FDA (USA) |
Safety, efficacy, environmental standards |
Need for extensive clinical data, eco-friendly packaging approvals |
| EMA (EU) |
Environmental policies, safety data for contrast media |
Emphasis on biodegradable packaging, low-adverse-reaction formulations |
| CFDA (China) |
Cost-effectiveness, local manufacturing |
Opportunities for regional manufacturing, localized formulations |
Regulatory approval timelines are approximately 12–24 months, with clear documentation and safety data required.
Comparison with Competitors
| Parameter |
Ultravis 300 (High-Osmolar) |
Low-Osmolar Alternatives |
Iso-Osmolar Agents |
| Osmolarity |
760 mOsm/kg |
500–620 mOsm/kg |
290–310 mOsm/kg |
| Safety Profile |
Higher adverse reactions |
Moderate, better safety |
Best safety profile |
| Cost |
Moderate |
High |
High |
| Packaging |
Plastic container focus |
Plastic and glass focus |
Usually glass, expanding to plastics |
| Market Access |
Mature markets |
Expanding markets |
Niche segments |
Future Growth Drivers and Opportunities
-
Emerging Markets Expansion: Increasing healthcare infrastructure investments in Asia-Pacific, Latin America, and Africa.
-
Environmental Initiatives: Adoption of biodegradable plastics and eco-designs.
-
Innovations in Contrast Media: Development of tailored formulations with improved safety profiles to replace existing high-osmolar agents.
-
Digital Health Integration: Improved compatibility with digital imaging equipment and reporting systems.
Potential Risks
| Risk |
Mitigation Strategies |
| Regulatory Delays |
Engage early with authorities, ensure compliance with evolving standards |
| Market Saturation |
Diversify portfolio with newer contrast agents, geographic expansion |
| Environmental Regulations |
Invest in green packaging developments, proactive sustainability policies |
| Supply Chain Disruptions |
Develop local manufacturing, diversify raw material sourcing |
Key Takeaways
-
Ultravis 300 in plastic containers is positioned within a growing diagnostic imaging contrast agent market driven by technological, regulatory, and environmental factors.
-
Market growth is projected at ~6.2% CAGR from 2023–2028, reaching ~USD 792 million globally.
-
Transitioning to environmentally friendly plastic packaging is strategic, enhancing safety, logistics, and regulatory compliance.
-
Competition from low- and iso-osmolar contrast agents persists, necessitating innovation and differentiation strategies.
-
Markets in Asia-Pacific and Latin America present significant growth opportunities due to infrastructure expansion and increased healthcare expenditure.
-
Regulatory landscapes are evolving to favor sustainable packaging and safer contrast media, influencing future product development.
FAQs
1. How does the shift to plastic containers impact the market for Ultravisist 300?
The shift to plastic containers reduces manufacturing costs, improves logistical efficiency, and aligns with environmental policies. It enhances safety by minimizing breakage risks and supports patient safety through pre-filled and single-dose formats. Regulatory compliance on eco-standards further incentivizes this transition.
2. What are the primary competitors to Ultravis 300, and how do they differ?
Main competitors include low-osmolar contrast agents like Iohexol and iodixanol, which offer improved safety profiles but at higher costs. Iso-osmolar agents like iodixanol provide superior safety but are more expensive and less widely used due to cost considerations.
3. What regional factors influence the revenue trajectory of Ultravis 300?
Developed markets such as North America and Europe have mature, regulated environments with steady growth, while emerging markets like China and India show accelerated demand driven by expanding healthcare infrastructure and lower procurement costs. Regulatory approvals and reimbursement policies also significantly impact regional performance.
4. How do regulatory bodies influence the future landscape of contrast media?
Regulatory agencies prioritize patient safety, environmental sustainability, and product efficacy. Stringent approval processes, especially concerning environmental standards, push manufacturers toward eco-friendly packaging and safer formulations, directly impacting Ultravisvist 300’s market strategy.
5. What innovations could reshape the market for contrast agents in the next decade?
Development of non-iodinated, targeted molecular imaging agents, improved safety profiles with minimal adverse reactions, biodegradable packaging, and integration with digital imaging technologies are likely to redefine the market landscape.
References
[1] Market Research Future, "Contrast Media Market Growth," 2022.
[2] IQVIA, "Global Contrast Media Market Report," 2022.
[3] Industry Manufacturing Reports, "Packaging Trends in Medical Devices," 2021.
